Form 4: STAAR Surgical CEO Thomas Frinzi Granted Stock Options and Restricted Stock Units

Thomas Frinzi, CEO of STAAR Surgical, received stock options and restricted stock units on March 12, 2024, according to a Form 4 filing with the SEC.

Summary

• Thomas G. Frinzi, the President and CEO of STAAR Surgical Co., was granted restricted stock units (RSUs) and stock options on March 12, 2024.
• The grant includes 74,389 RSUs, each representing the right to receive one share of STAAR Surgical's common stock upon vesting.
• These RSUs will vest in three equal installments: 24,796 shares on March 12, 2025, 24,796 shares on March 12, 2026, and 24,797 shares on March 12, 2027.
• Frinzi also received options to purchase 66,627 shares of common stock at an exercise price of $37.64 per share.
• The stock options vest as to 1/3 (22,209 shares) on March 12, 2025, with the remaining 2/3 (44,418 shares) vesting monthly over the following 24 months, concluding on March 12, 2027.
• A Limited Power of Attorney was executed on March 11, 2024, authorizing Nathaniel Sisitsky and Patrick Williams to act on Frinzi's behalf for Section 16 reporting obligations.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.
• The vesting schedule of the RSUs and stock options encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grants suggest an expectation of continued leadership and value creation by the CEO.

Industry Context

Equity grants are a common practice in the medical device industry to incentivize executives and align their interests with shareholders. The size and vesting schedule of the grants are typical for a CEO of a company of STAAR Surgical's size and stage.

Comparison to Industry Standards

• Comparing STAAR Surgical's executive compensation practices to those of similar-sized medical device companies like Glaukos or InMode reveals that equity grants are a standard component of executive pay.
• The vesting schedules are also in line with industry norms, typically ranging from three to four years to encourage long-term commitment.
• The specific value of the grants would need to be compared against revenue and market capitalization metrics to determine if they are above or below industry averages.

Stakeholder Impact

• Shareholders: The equity grants align the CEO's interests with shareholder value creation.
• Employees: The grants can boost employee morale by demonstrating confidence in the company's future.
• CEO: The grants provide a significant incentive for the CEO to drive long-term growth and profitability.

Key Dates